[1] [1] XU H, CHEN X Y, SUN Y, et al. Comprehensive molecular characterization of long-term glioblastoma survivors[J]. Cancer Letters, 2024, 593: 216938

[2] [2] LIU J Y, YANG F, HU J Q, et al. Nanoparticles for efficient drug delivery and drug resistance in glioma: new perspectives[J]. CNS Neuroscience & Therapeutics, 2024, 30(5): e14715

[3] [3] LOUIS D N, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathologica, 2016, 131(6): 803

[4] [4] VIGNESWARAN K, NEILL S, HADJIPANAYIS C G. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification[J]. Annals of Translational Medicine, 2015, 3(7): 95

[5] [5] LOUIS D N, PERRY A, WESSELING P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro-oncology, 2021, 23(8): 1231

[6] [6] SAHM F, BRANDNER S, BERTERO L, et al. Molecular diagnostic tools for the World Health Organization (WHO)2021 classification of gliomas, glioneuronal and neuronal tumors: an EANO guideline[J]. Neuro-oncology, 2023, 25(10): 1731

[7] [7] GARLAND P, QURAISHE S, FRENCH P, et al. Expression of the MAST family of serine/threonine kinases[J]. Brain Research, 2008, 1195: 12

[8] [8] MCMICHAEL G, BAINBRIDGE M N, HAAN E, et al. Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy[J]. Molecular Psychiatry, 2015, 20(2): 176

[9] [9] BEN-MAHMOUD A, AL-SHAMSI A M, ALI B R, et al. Evaluating the role ofMAST1as an intellectual disability disease gene: identification of a novelde novovariant in a patient with developmental disabilities[J]. Journal of Molecular Neuroscience, 2020, 70(3): 320

[10] [10] YI S, TANG X L, CHEN F, et al. A genetic variant in theMAST1gene is associated with mega-corpus-callosum syndrome with hypoplastic cerebellar vermis, in a fetus[J]. Molecular Genetics & Genomic Medicine, 2024, 12(1): e2358

[11] [11] SLOBODA N, RENARD E, LAMBERT L, et al.MAST1-related mega-corpus-callosum syndrome with central hypogonadism[J]. European Journal of Medical Genetics, 2023, 66(11): 104853

[12] [12] TOMOSHIGE K, MATSUMOTO K, TSUCHIYA T, et al. Germline mutations causing familial lung cancer[J]. Journal of Human Genetics, 2015, 60(10): 597

[13] [13] GIRARD E, EON-MARCHAIS S, OLASO R, et al. Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing[J]. International Journal of Cancer, 2019, 144(8): 1962

[14] [14] OISHI T, IINO K, OKAWA Y, et al. DNA methylation analysis in malignant pheochromocytoma and paraganglioma[J]. Journal of Clinical & Translational Endocrinology, 2017, 7: 12

[15] [15] MAO X H, YE Q, ZHANG G B, et al. Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer[J]. World Journal of Surgical Oncology, 2021, 19(1): 29

[16] [16] YU X F, SHENG P, SUN J, et al. The circular RNA circMAST1promotes hepatocellular carcinoma cell proliferation and migration by sponging miR-1299 and regulating CTNND1 expression[J]. Cell Death & Disease, 2020, 11(5): 340

[17] [17] ZHANG C Y, YUAN L, ZOU Q J, et al. CircMAST1 inhibits cervical cancer progression by hindering the N4-acetylcytidine modification of YAP mRNA[J]. Cellular & Molecular Biology Letters, 2024, 29(1): 25

[18] [18] ROBINSON D R, KALYANA-SUNDARAM S, WU Y M, et al. Functionally recurrent rearrangements of theMASTkinase and Notch gene families in breast cancer[J]. Nature Medicine, 2011, 17(12): 1646

[19] [19] WEI S T, ZHANG J, SHI R, et al. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma[J]. Frontiers in Oncology, 2022, 12: 944000

[20] [20] RUMPF M, PAUTZ S, DREBES B, et al. Microtubule-associated serine/threonine (MAST) kinases in development and disease[J]. International Journal of Molecular Sciences, 2023, 24(15): 11913

[21] [21] PAN C Y, CHUN J, LI D, et al. Hsp90B enhances MAST1-mediated cisplatin resistance by protectingMAST1from proteosomal degradation[J]. The Journal of Clinical Investigation, 2019, 129(10): 4110

[22] [22] KARAPURKAR J K, COLACO J C, SURESH B, et al. USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinatingMAST1protein in cancer cells[J]. Cellular and Molecular Life Sciences, 2024, 81(1): 145

[23] [23] JING T R, MA J, ZHAO H Q, et al. MAST1 modulates neuronal differentiation and cell cycle exitviaP27 in neuroblastoma cells[J]. FEBS Open Bio, 2020, 10(6): 1104

[24] [24] FELISTIA Y, WEN P Y. Molecular profiling and targeted therapies in gliomas[J]. Current Neurology and Neuroscience Reports, 2023, 23(10): 627

[25] [25] MISHCHENKO T A, TURUBANOVA V D, GORSHKOVA E N, et al. Targeting immunogenic cell death for glioma immunotherapy[J]. Trends in Cancer, 2024, 10(1): 8

[26] [26] TRIPATHY R, LECA I, VAN DIJK T, et al. Mutations inMAST1cause mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations[J]. Neuron, 2018, 100(6): 1354

[27] [27] JIN L T, CHUN J, PAN C Y, et al. MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation[J]. Cancer Cell, 2018, 34(2): 315

[28] [28] PAN C Y, KANG J, HWANG J S, et al. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistancevia MAST1[J]. Nature Communications, 2021, 12(1): 4960